Department of General Surgery, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd 8915887857, Iran.
Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH 43210, USA.
Cells. 2024 Jan 29;13(3):252. doi: 10.3390/cells13030252.
Cachexia is a condition characterized by substantial loss of body weight resulting from the depletion of skeletal muscle and adipose tissue. A considerable fraction of patients with advanced cancer, particularly those who have been diagnosed with pancreatic or gastric cancer, lung cancer, prostate cancer, colon cancer, breast cancer, or leukemias, are impacted by this condition. This syndrome manifests at all stages of cancer and is associated with an unfavorable prognosis. It heightens the susceptibility to surgical complications, chemotherapy toxicity, functional impairments, breathing difficulties, and fatigue. The early detection of patients with cancer cachexia has the potential to enhance both their quality of life and overall survival rates. Regarding this matter, blood biomarkers, although helpful, possess certain limitations and do not exhibit universal application. Additionally, the available treatment options for cachexia are currently limited, and there is a lack of comprehensive understanding of the underlying molecular pathways associated with this condition. Thus, this review aims to provide an overview of molecular mechanisms associated with cachexia and potential therapeutic targets for the development of effective treatments for this devastating condition.
恶病质是一种以骨骼肌和脂肪组织消耗导致体重明显下降为特征的病症。相当一部分晚期癌症患者,特别是被诊断患有胰腺癌、胃癌、肺癌、前列腺癌、结肠癌、乳腺癌或白血病的患者,都会受到这种病症的影响。这种综合征在癌症的各个阶段都有表现,且与预后不良相关。它增加了手术并发症、化疗毒性、功能障碍、呼吸困难和疲劳的易感性。早期发现癌症恶病质患者,有可能提高他们的生活质量和总体生存率。关于这一点,血液生物标志物虽然有帮助,但也存在一定的局限性,并且不是普遍适用的。此外,目前恶病质的治疗选择有限,并且对与这种病症相关的潜在分子途径缺乏全面的了解。因此,本综述旨在概述与恶病质相关的分子机制以及开发这种破坏性病症的有效治疗方法的潜在治疗靶点。